# Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

> **NCT01355562** · PHASE2 · WITHDRAWN · sponsor: **Loma Linda University**

## Conditions studied

- Melanoma
- Metastatic Kidney Cancer

## Interventions

- **DRUG:** Interleukin-2 (IL-2)

## Key facts

- **NCT ID:** NCT01355562
- **Lead sponsor:** Loma Linda University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Primary Investigator is no longer employed at LLU as of 02/29/12.
- **Last updated:** 2020-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355562, "Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01355562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*